| P50 | author | Krishnaraj Rajalingam | Q87655285 |
| | Lisa J Crawford | Q96303458 |
| | Roisin M McAvera | Q96303460 |
| P2093 | author name string | Dharminder Chauhan | |
| | Andrew D Chantry | |
| | Alexandra E Irvine | |
| | David C Campbell | |
| | Michelle A Lawson | |
| | Aswini Krishnan | |
| | Claudia Hamilton | |
| | Jennifer M Down | |
| | Jonathan J Morgan | |
| | Treen C Morris | |
| P2860 | cites work | The Influence of Metabolism on Drug Response in Cancer | Q59136910 |
| | Carfilzomib for relapsed and refractory multiple myeloma | Q64083853 |
| | CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy | Q64093247 |
| | Targeting MYC in multiple myeloma | Q87842402 |
| | Ubiquitination: Friend and foe in cancer | Q88976865 |
| | HUWE1 controls the development of non-small cell lung cancer through down-regulation of p53 | Q90352927 |
| | Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment | Q90919275 |
| | Ubiquitin ligases HUWE1 and NEDD4 cooperatively control signal-dependent PRC2-Ezh1α/β-mediated adaptive stress response pathway in skeletal muscle cells | Q92128904 |
| | Multiple myeloma: Every year a new standard? | Q92675436 |
| | Non-proteolytic ubiquitination of Hexokinase 2 by HectH9 controls tumor metabolism and cancer stem cell expansion | Q92761067 |
| | Ixazomib for the treatment of multiple myeloma | Q93028409 |
| | The power of proteasome inhibition in multiple myeloma | Q93067519 |
| | Proteogenomics analysis unveils a TFG-RET gene fusion and druggable targets in papillary thyroid carcinomas | Q94452068 |
| | A Structural Element within the HUWE1 HECT Domain Modulates Self-ubiquitination and Substrate Ubiquitination Activities | Q27658641 |
| | The ubiquitin ligase HectH9 regulates transcriptional activation by Myc and is essential for tumor cell proliferation | Q28280330 |
| | Homeostatic defects in B cells deficient in the E3 ubiquitin ligase ARF-BP1 are restored by enhanced expression of MYC | Q33828914 |
| | HUWE1 is a molecular link controlling RAF-1 activity supported by the Shoc2 scaffold | Q34298040 |
| | HUWE1 and TRIP12 collaborate in degradation of ubiquitin-fusion proteins and misframed ubiquitin | Q34500475 |
| | NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease | Q35175289 |
| | Tumor cell-specific inhibition of MYC function using small molecule inhibitors of the HUWE1 ubiquitin ligase | Q35275756 |
| | The E3 ubiquitin ligase Mule acts through the ATM-p53 axis to maintain B lymphocyte homeostasis. | Q35679564 |
| | Characterization of ARF-BP1/HUWE1 interactions with CTCF, MYC, ARF and p53 in MYC-driven B cell neoplasms | Q36057221 |
| | A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance | Q36338365 |
| | Mule/Huwe1/Arf-BP1 suppresses Ras-driven tumorigenesis by preventing c-Myc/Miz1-mediated down-regulation of p21 and p15 | Q36902911 |
| | HUWE1 is a critical colonic tumour suppressor gene that prevents MYC signalling, DNA damage accumulation and tumour initiation | Q37618001 |
| | Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance | Q38743857 |
| | HUWE1 interacts with PCNA to alleviate replication stress | Q38773179 |
| | The ubiquitin ligase HERC4 mediates c-Maf ubiquitination and delays the growth of multiple myeloma xenografts in nude mice. | Q38798189 |
| | The Role of c-MYC in B-Cell Lymphomas: Diagnostic and Molecular Aspects | Q39221506 |
| | Identification of the APC/C co-factor FZR1 as a novel therapeutic target for multiple myeloma | Q41971182 |
| | HUWE1 ubiquitylates and degrades the RAC activator TIAM1 promoting cell-cell adhesion disassembly, migration, and invasion | Q42101475 |
| | Inhibition of the deubiquitinase USP5 leads to c-Maf protein degradation and myeloma cell apoptosis | Q42261427 |
| | A conformational switch regulates the ubiquitin ligase HUWE1. | Q42321543 |
| | Ubiquitin Linkage-Specific Affimers Reveal Insights into K6-Linked Ubiquitin Signaling | Q42377050 |
| | Glutaminase inhibition in multiple myeloma induces apoptosis via MYC degradation. | Q45925019 |
| | Impaired oxidative stress response characterizes HUWE1-promoted X-linked intellectual disability | Q47093588 |
| | QuPath: Open source software for digital pathology image analysis | Q47108040 |
| | E3 ubiquitin ligases in cancer and implications for therapies | Q47636038 |
| | HUWE1 variants cause dominant X-linked intellectual disability: a clinical study of 21 patients. | Q48227714 |
| | The K48-K63 Branched Ubiquitin Chain Regulates NF-κB Signaling | Q48964297 |
| | Huwe1 Sustains Normal Ovarian Epithelial Cell Transformation and Tumor Growth through the Histone H1.3-H19 Cascade. | Q50902450 |
| | Resistance to proteasome inhibitors and other targeted therapies in myeloma. | Q53693372 |
| | Metabolic Features of Multiple Myeloma. | Q53694850 |
| | Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma | Q57117709 |
| | Ubiquitination by HUWE1 in tumorigenesis and beyond | Q57161316 |
| | Alterations of ubiquitin ligases in human cancer and their association with the natural history of the tumor | Q57964092 |
| | Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma | Q58792995 |
| P577 | publication date | 2020-06-10 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma | |